Compare Incyte Corporation (INCY) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Virgin Galactic Holdings, Inc. — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while Virgin Galactic Holdings, Inc. trades at $2.7 (market cap $329.06M). The key difference: Incyte Corporation is far larger — about 70.2× Virgin Galactic Holdings, Inc.'s market cap, and Incyte Corporation is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | SPCE | |
|---|---|---|
Market Cap | $23.11B | $329.06M |
Sector | Health | Industrials |
52-Week High | $118.52 | $7.52 |
52-Week Low | $67.38 | $2.17 |
Enterprise Value | $19.13B | $428.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Virgin Galactic (SPCE) trades at $2.58, up 0.78% on the day, amid a bearish technical outlook and deeply negative profitability. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility in the space sector, with SPCE shares reacting to broader industry movements and specific corporate actions like stock awards.
The outlook remains highly speculative, with substantial execution risks and cash burn posing challenges. Investment opportunity hinges on future commercialization success, but current fundamentals and analyst divergence suggest caution. Key risks include reliance on future funding and intense competition in the space tourism sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
